Form 4 for ENTA ENANTA PHARMACEUTICALS INC
Accepted 2022-12-19 00:00:00 ET · period of report 2022-12-19 · accession 0001062993-22-024173 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-19 | 2022-12-19 | ENTA | Luly Jay R. | Pres, CEO, Dir | M - OptEx | $27.58 | +14.5K | 788.3K | +2% | +$399.9K |
| D | 2022-12-19 | 2022-12-19 | ENTA | Luly Jay R. | Pres, CEO, Dir | M - OptEx | $0.00 | -14.5K | 55.5K | -21% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-19 | M | A | 14,500 | $27.58 | 788,305 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-12-19 | M | D | 14,500 | $0.00 | 55,500 | D | $27.58 · — to 2023-12-05 | 14,500 Common Stock | (F1) 100% of the shares subject to the option are fully vested and exercisable. |